BIOTRANSFORMATIONS OF ANTHRACYCLINONES IN STREPTOMYCES-COERULEORUBIDUS AND STREPTOMYCES-GALILAEUS
BIOTRANSFORMATIONS OF ANTHRACYCLINONES IN STREPTOMYCES-COERULEORUBIDUS AND STREPTOMYCES-GALILAEUS
复制标题
DOI：
10.1007/bf02927295
复制
发表时间：
1979-01-01
影响因子：
2.6
通讯作者：
VANEK, Z
中科院分区：
文献类型：
--
作者：
BLUMAUEROVA, M;KRALOVCOVA, E;VANEK, Z
生物转化外源性道诺霉素酮、13-二氢道诺霉素酮、阿克拉维酮、7-脱氧阿克拉维酮、ε-玫瑰霉素酮，ε-异红霉素酮和ε-在以下菌株的深层培养物中研究了吡咯霉素酮：野生S. coeruleorubidus JA 10092（W1）及其改进的变体39-146和84-17（P1型），其产生柔红霉素酮和13-二氢柔红霉素酮的糖苷，以及ε- rhodomycinone、13-dihydrodaunomycinone和7-deoxy-13-dihydrodaunomycinone; coeruleorubidus（A，B，C，D，E）的糖苷合成受阻，游离蒽环酮的产生不同; galilaeus JA 3043（W2）及其产生ε-葡糖苷的改进变体G-167（P2）吡咯霉素酮和阿克拉维酮以及两种糖苷配基的7-脱氧和双脱水衍生物; galilaeus（F和G）在糖苷的生物合成中被阻断，并且在蒽环酮的出现上不同。观察到下列生物转化：道诺霉素酮→13-二氢道诺霉素酮和7-脱氧-13-二氢道诺霉素酮（所有菌株）; 13-二氢道诺霉素酮。7-脱氧-13-二氢柔红霉素酮（所有菌株）;柔红霉素酮或13-二氢柔红霉素酮→与代谢物W1和P1相同的柔红霉素酮和13-二氢柔红霉素酮的糖苷（A型），或仅柔红霉素酮的单一糖苷（E型）;ε-玫瑰霉素酮（A型和B型）; 7-脱氧阿克拉维酮和双脱水阿克拉维酮（C型）; ε-玫瑰霉素酮. zeta. -玫瑰霉素酮（C、E型）; ε-玫瑰霉素酮ε-糖苷玫瑰霉素酮（W2、P2型）; ε-异红霉素酮ε-糖苷异红霉素酮（W2、P2型）; ε-吡咯霉素酮ε的糖苷，吡咯霉素酮（W1、P1型）。7-脱氧克拉维酮在所有测试中保持完整。外源性道诺霉素酮抑制W1和P1中其自身糖苷的生物合成;它同时增加了ε-葡糖苷的产生。P1中的玫瑰霉素酮。
The ability to transform biologically exogenous daunomycinone, 13-dihydrodaunomycinone, aklavinone, 7-deoxyaklavinone, .epsilon.-rhodomycinone, .epsilon.-isorhodomycinone and .epsilon.-pyrromycinone was studied in submerged cultures of the following strains: wild S. coeruleorubidus JA 10092 (W1) and its improved variants 39-146 and 84-17 (type P1) producing glycosides of daunomycinone and of 13-dihydrodaunomycinone, together with .epsilon.-rhodomycinone, 13-dihydrodaunomycinone and 7-deoxy-13-dihydrodaunomycinone; in 5 mutant types of S. coeruleorubidus (A, B, C, D, E) blocked in the biosynthesis of glycosides and differing in the production of free anthracyclinones; in the wild S. galilaeus JA 3043 (W2) and its improved variant G-167 (P2) producing glycosides of .epsilon.-pyrromycinone and of aklavinone together with 7-deoxy and bisanhydro derivatives of both aglycones; in 2 mutant types S. galilaeus (F and G) blocked in biosynthesis of glycosides and differing in the occurrence of anthracyclinones. The following bioconversions were observed: daunomycinone .fwdarw. 13-dihydrodaunomycinone and 7-deoxy-13-dihydrodaunomycinone (all strains); 13-dihydrodaunomycinone .fwdarw. 7-deoxy-13-dihydrodaunomycinone (all strains); daunomycinone or 13-dihydrodaunomycinone .fwdarw. glycosides of daunomycinone and of 13-dihydrodaunomycinone, identical with metabolites W1 and P1 (type A), or only a single glycoside of daunomycinone (type E); aklavinone .fwdarw. .epsilon.-rhodomycinone (types A and B); aklavinone .fwdarw. 7-deoxyaklavinone and bisanhydroaklavinone (type C); .epsilon.-rhodomycinone .fwdarw. .zeta.-rhodomycinone (types C, E); .epsilon.-rhodomycinone .fwdarw. glycosides of .epsilon.-rhodomycinone (types W2, P2); .epsilon.-isorhodomycinone .fwdarw. glycosides of .epsilon.-isorhodomycinone (types W2, P2); .epsilon.-pyrromycinone .fwdarw. a glycoside of .epsilon.-pyrromycinone (types W1, P1). 7-Deoxyaklavinone remained intact in all tests. Exogenous daunomycinone suppressed the biosynthesis of its own glycosides in W1 and P1; it simultaneously increased the production of .epsilon.-rhodomycinone in P1.